Loading
Build a public library in which every phase 3 cancer trial is paired with a real-world emulation in federated hospital data, publishing how far the two agree in direction, magnitude and confidence interval overlap. Oncology needs its own calibration set because RCT-DUPLICATE covered mostly cardiometabolic disease, and it would map which question types can be trusted.
RCT-DUPLICATE calibrated real-world methods against trials mostly in cardiometabolic disease; oncology, with its time-varying treatments and surrogate endpoints, needs its own calibration set. The proposal funds a standing programme that emulates every phase 3 oncology trial with a real-world counterpart in federated data, publishes agreement metrics (direction, magnitude, confidence interval overlap), and maintains a public map of which question types (first-line comparisons, sequencing, dose) are emulable.
Shares Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval, Real-world evidence, Weak real-world evidence and registries.
Shares Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval, Real-world evidence, Weak real-world evidence and registries.
Shares Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval, Real-world evidence, Weak real-world evidence and registries.
Shares Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval, Real-world evidence, Weak real-world evidence and registries.
Shares Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval, Real-world evidence, Weak real-world evidence and registries.
Shares Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval, Real-world evidence, Weak real-world evidence and registries.
Shares Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval, Real-world evidence, Weak real-world evidence and registries.
Shares Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval, Real-world evidence, Weak real-world evidence and registries.